Drug intelligence / Profile preview

PLX015

Development stage: Preclinical
Lead developer: ProLynx
Modality: Recombinant Proteins and Enzymes

Overview

PLX015 is a preclinical drug candidate developed by Prolynx LLC, functioning as an Interleukin-15 (IL-15) modulator. IL-15 is a cytokine vital for the immune system, particularly in activating and proliferating natural killer (NK) cells and CD8+ T cells. As an IL-15 modulator, PLX015 is being developed for therapeutic areas in neoplasms, likely aiming to enhance anti-tumor immune responses by stimulating these immune cells.

Targets

IL15RA (Interleukin-15 receptor subunit alpha)IL2RB (IL-2 receptor beta chain)

Beyond the preview

Go deeper on PLX015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLX015.

Explore the full profile